Ethylphenidate (EP) is a potent psychostimulant that acts as both a dopamine reuptake inhibitor and norepinephrine reuptake inhibitor, meaning it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters in the brain, by binding to, and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft.
It is most commonly formed when ethanol and methylphenidate are coingested, via hepatic transesterification. Ethylphenidate formation appears to be more common when large quantities of methylphenidate and alcohol are consumed at the same time, such as in non-medical use or overdose scenarios. This carboxylesterase-dependent transesterification process is also known to occur when cocaine and alcohol are consumed together, forming cocaethylene.
Ethylphenidate is more selective to the dopamine transporter (DAT) than methylphenidate, having approximately the same efficacy as the parent compound, but has significantly less activity on the norepinephrine transporter (NET). It has a near-identical dopaminergic pharmacodynamic profile as methylphenidate, which is primarily responsible for its euphoric and reinforcing effects.
The eudysmic ratio for ethylphenidate is superior to that of methylphenidate.
|Compound||Binding DAT||Binding NET||Uptake DA||Uptake NE|
Other articles related to "ethylphenidate":
... Ethylphenidate is not controlled in the Netherlands, as the Opium Law does not cover it, nor is there any law covering analogs of controlled drugs (methylphenidate is covered) ... Ethylphenidate is not explicitly controlled in US but it could possibly be considered an analog of a Schedule II substance (methylphenidate) under the Federal Analog Act ... Ethylphenidate is illegal in Sweden as of 15 December 2012 Ethylphenidate is not controlled in the UK, as there is no generic legislation for ritalinic esters, nor is it explicitly named in the Misuse ...